The Research Article by Oksana Fihurka, Vasyl Sava & Juan Sanchez-Ramos, ‘Dual-function hybrid nanoparticles with gene silencing and anti-inflammatory effects’, which appeared in the April 2022 issue of Nanomedicine 17(9) 577–590 (2022), was published with incorrect figure legends for Figures 3 and 4. These figure legends have been amended as follows:
Figure 3. Comparative transfection efficacy of chitosan and chitosan lactate nanoparticles and hybrid nanoparticles. (A) Kinetic curves obtained by extrapolation experimental data (Table 2) with proposed logistic function. Fitting parameters R and the correspondent Pearson’s coefficients (P) for the experimental and calculated data were as follows: R = 1.5 and P = 0.998 for the CSL NP; R = 1.1 and P = 0.995 for the CSL HNP; R = 1.05 and P = 0.997 for the CS NP; R = 0.89 and P = 0.997 for the CS HNP.(B) 50% transfection level for pDNA carried by different nanocarriers in BMMS cell culture.
CS: Chitosan; CSL: Chitosan lactate; HNP: Hybrid nanoparticle; NP: Nanoparticle.
Figure 4. In vitro HD gene silencing efficacy of two anti-HTT siRNAs and nontargeting control siRNA (NTC) loaded into commercially available Lipofectamine 3000. The BMMS cells were plated 48 h before siRNA was added for 24 h in OptiMEM medium. The graph represents the changes in mutant HTT gene expression RQ-1. The data are given as mean values ± SEM of triplicates. Statistical analysis was conducted using one-way ANOVA followed by Tukey post hoc multiple comparison test. Both siRNA preparations significantly reduced HTT expression compared to NTC.
*p < 0.001.
NTC: No template control.
The editors of Nanomedicine would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.